Subba Reddy Katamreddy
Research Triangle Park
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Subba Reddy Katamreddy.
Bioorganic & Medicinal Chemistry Letters | 2008
Jing Fang; Adwoa Akwabi-Ameyaw; Jonathan E. GlaxoSmithKline Britton; Subba Reddy Katamreddy; Frank Navas; Aaron B. Miller; Shawn P. Williams; David W. Gray; Lisa A. Orband-Miller; Jean Shearin; Dennis Heyer
A series of estrogen receptor ligands based on a 3-alkyl naphthalene scaffold was synthesized using an intramolecular enolate-alkyne cycloaromatization as the key step. Several of these compounds bearing a C6-OH group were shown to be high affinity ligands. All compounds had similar ERalpha and ERbeta binding affinity ranging from micromolar to low nanomolar.
Journal of Medicinal Chemistry | 2012
Subba Reddy Katamreddy; Andrew J. Carpenter; Carina Ammala; Eric E. Boros; Ron L. Brashear; Celia P. Briscoe; Sarah R. Bullard; Richard Dana Caldwell; Christopher R. Conlee; Dallas K. Croom; Shane M. Hart; Dennis Heyer; Paul R. Johnson; Jennifer A. Kashatus; Doug Minick; Gregory Peckham; Sean Ross; Shane Roller; Vicente Samano; Howard Sauls; Sarva M. Tadepalli; James B. Thompson; Yun Xu; James M. Way
GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119 (GPR119) agonists, and lead optimization efforts led to the identification of 1-methylethyl 4-({7-[2-fluoro-4-(methylsulfonyl)phenyl]-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)-1-piperidinecarboxylate (GSK1104252A) (3), a potent and selective GPR119 agonist. Compound 3 showed excellent pharmacokinetic properties and sufficient selectivity with in vivo studies supporting a role for GPR119 in glucose homeostasis in the rodent. Thus, 3 appeared to modulate the enteroinsular axis, improve glycemic control, and strengthen previous suggestions that GPR119 agonists may have utility in the treatment of type 2 diabetes.
Archive | 2007
Jing Fang; Jun Tang; Andrew J. Carpenter; Gregory Peckham; Christopher R. Conlee; Kien S. Du; Subba Reddy Katamreddy
Archive | 2004
Jonathan E. GlaxoSmithKline Britton; Jing GlaxoSmithKline Fang; Dennis GlaxoSmithKline Heyer; Aaron B. Miller; Frank Navas; Terrence Lee Jr. GlaxoSmithKline Smalley; William J. Zuercher; Subba Reddy Katamreddy
Archive | 2004
John F. Eaddy; Dennis Heyer; Amarjit Sab Randhawa; Vicente Samano; John A. Ray; Subba Reddy Katamreddy; Michael Tolar Martin; Michael Scott GlaxoSmithKline Mcclure
Archive | 2007
Jing Fang; Jun Tang; Andrew J. Carpenter; Gregory Peckham; Christopher R. Conlee; Kien S. Du; Subba Reddy Katamreddy; Brian Andrew Chauder
Archive | 2007
Jing Fang; Jun Tang; Andrew J. Carpenter; Gregory Peckham; Christopher R. Conlee; Kien S. Du; Subba Reddy Katamreddy; Brian Andrew Chauder
Archive | 2007
Subba Reddy Katamreddy; Richard Dana Caldwell; Dennis Heyer; Vincente Samano; James B. Thompson; Andrew J. Carpenter; Christopher R. Conlee; Eric E. Boros; Brian Thompson
Archive | 2007
Andrew J. Carpenter; Christopher R. Conlee; Kien S. Du; Jing Fang; Subba Reddy Katamreddy; Gregory Peckham; Jun Tang
Archive | 2007
Jing Fang; Jun Tang; Andrew J. Carpenter; Gregory Peckham; Christopher R. Conlee; Kien S. Du; Subba Reddy Katamreddy; Brian Andrew Chauder